Nasdaq CM: RVPH

Virtual KOL Event to Discuss Topline Data From Phase 3 Clinical RECOVER Trial of Brilaroxazine in Schizophrenia


Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a clinical-stage pharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases.

Reviva uses a chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Reviva’s pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house.

Latest News



Our leadership team is comprised of experienced and qualified professionals associated with pharmaceutical and medical industries as well as business experts focused on providing value to our patients, our partners, and our shareholders.

Stock Information

Reviva Pharmaceuticals

Nasdaq CM: RVPH

Investor Contacts


Narayan Prabhu, CFO
Reviva Pharmaceuticals

Phone: 408.501.8881
Email: [email protected]

Investor Relations

Ben Shamsian
Lytham Partners, LLC

Phone: 602.889.9700
Email: [email protected]

Transfer Agent

Continental Stock Transfer & Trust
1 State Street, 30th Floor
New York, NY 10004-1561

Phone: 212.509.4000
Email: [email protected]